Minimal Clinically Important Differences in COPD Lung Function

REFERENCES

• Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932–946. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fabbri L, Pauwels R A, Jurd S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 2004; 1:105–141.
   PubMedGoogle Scholar
• Jaesche R, Singer J, Guyatt G H. Measurement of health status ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407–415., [CROSSREF]
   PubMedGoogle Scholar
• Beaton D E, Boers M, Wells G A. Many faces of the minimal clinically important differences (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002; 14:109–114. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wyrwich K W, Tierney W M, Wolinsky F D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52(9):861–873. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152:1107–1136. [CSA]
   PubMed Web of Science ®Google Scholar
• Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the porgession of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58(11):937–941. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vestbo J, TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004 Aug; 24(2):206–210. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Taskin D P, Pauwels R A, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long term functional impacts of tiotropium in COPD, the uplift trial. J COPD 2004; 1(2):303–312.
   PubMedGoogle Scholar
• Decramer M, Dekhuijzen P N, Troosters T, van Herwaarden C, et al. The bronchitis randomized on NAC Cost-utility study (BRONCUS): hypothesis and design. BRONCUS-trial committee. Lancet 2005, In press.
   PubMedGoogle Scholar
• The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998; 158:49–59. [CSA]
   PubMed Web of Science ®Google Scholar
• Scanlon P D, Connett J E, Waller L A, Altose M D, Bailey W, Buist S S, Tashkin D P, Lung Health Study Research Group. Smoking Cessation and lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000; 162:381–390.
   Google Scholar
• Celli R B, Cote C G, Martin J M, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med 2004; 350:1005–1012. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nishamura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434–1440. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hansen E F, Phanareth K, Laursen L S, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1267–1271. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Casabari R, Briggs D D Jr, Donohue J F, Serby C W, Menjoge S S, Witek T J Jr, US Tiotropium Study Group. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000; 118:1294–1302. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Donohue J F, van Noord J A, Bateman E D, Langley S J, Lee A, Witek T J Jr, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47–55. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Donohue J F, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3(3):173–181. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Hanania N A, Darken P, Horstam D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 µg/ salmeterol [50 µg]) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834–843. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084–1091. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhort A PM, Bantje T A, Kesten S, Korducki L, Cornelissen P JG, Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209–216. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399–404. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gross N J, Petty T L, Friedman M, Skordin M S, Silvers G W, Donohue J F. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis May 1989; 139(5):1188–1191. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine B E, Thomson M H, Till D, Kottakis J, Cioppa G D, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058–1069. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Quanjer P H, Tammeling G J, Cotes J E, Pedersen O F, Peslin R, Yernault J C. Lung volumes and forced ventilatory flows, report working party standardization of lung function tests. Official statement of the European respiratory society. Eur Respir J 1993; 16(suppl):5–40.
   Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry; 1987 update. Am Rev Respir Dis 1987; 136:1286–1296.
   Google Scholar
• Hankinson J L, Bang K M. Acceptability and reproducibility criteria of the American thoracic society as observed in a sample of the general population. Am Rev Repsir Dis 1991; 143:516–521.
   PubMed Web of Science ®Google Scholar
• Schermer T R, Jacobs J E, Chavannes N H, Hartman J, Folgering H T, Bottema B J, van Weel C. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003 Oct; 58(10):861–866. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Townsend M C, Hankinson J L, Lindesmith L A, Slivka W A, Stiver G, Ayres G T. Is my lung function really that good? Flow-type spirometer problems that elevate test results. Chest 2004; 125(5):1902–1909. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Santus P, Pecchiari M, Carlucci P, Boveri B, Di Marco F, Castagna F, Centanni S. Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. Eur Respir J 2003; 21(1):82–85. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sharafkhanek A, Officer T M, Goodnight-White S, Rodart J R, Borek A M. Novel method for measuring effects of gas compression on expiratory flow. Am J Physiol Regal Integr Comp Physiol 2004; 287:R479–R484.
   Google Scholar
• Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; 1:775–779.
   PubMed Web of Science ®Google Scholar
• Freedman S, Prowse K. How many blows make an FEV1? Lancet 1996; 2:618–619.
   Google Scholar
• Joyce D P, Jackevicius C, Chapman K R, McIvor R A, Kesten S. The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 2000 Jun; 37(4):3003–3018.
   Google Scholar
• Enright P L, Beck K C. Sherrill, repeatability of spirometry in 1,800 adult patients. Am J Respir and Crit Care Med 2004; 169:235–238. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tweeddale P M, Alexander F, McHardy G JR. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42:487–490. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wise R A, Connett J, Kurnow K, Grill J, Johnson L, Kanner R, Enright P, Lung Center Study Group. Selection of spirometric measurements in a clinical trial, the lung health study. Am J Respir Crit Care Med 1995; 151:1675–1681. [CSA]
   PubMedGoogle Scholar
• Brand P L, Quanjer P H, Postma D S, Kerstjens H A, Koeter G H, Dekhuijzen P N, Sluiter H J. Interpretation of bronchodilator response in patients with airways disease. The Dutch chronic non-specific lung disease (CNSLD) study group. Thorax 1992; 47(6):429–436. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hankinson J L, Crapo R O, Jensen R L. Spirometric referencevalues for the 6-s FVC maneuver. Chest 2003 Nov; 124(5):1805–1811. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Swanney M P, Jensen R L, Crichton D A, Beckert L E, Cardno L A, Crapo R O. FEV6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162(3):917–919. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Enright P L, Connett J E, Bailey W C. The FEV1/FEV6 predicts lung function decline in adult smokers. Respir Med 2002; 96:444–449. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Lam M, Webb K A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557–1565. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21:86–94. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Newton M F, O'Donnell D E, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121:1042–1050. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Redelmeier D A, Goldstein R S, Min S T, Hyland R H. Spirometry and dyspnea in patients with COPD: when small differenced mean little. Chest 1996; 109:1163–1168. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Santanello N C, Zhang J, Seidenberg B, Reiss T F, Barber B L. What are minimal important changes for asthma measures in a clinical trial?. Eur Respir J 1999; 14(1):23–27. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Niewoehner D E, Collins D, Erbland M L, Deaprtment of Veterans Affairs Cooperative Study Group. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:991201–991205.
   Google Scholar
• Singh J M, Palda V A, Stanbrook M B, Chapman K R. Corticosteroids therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2002; 162:2527–2536. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Davies L, Angus R M, Calverley P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354:456–460. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aaron S D, Vandemheen K L, Herbert P, Dale R, Stiell K T, Ahuja J, Dickinson G, Brison R, Rowe B H, Dreyer J, Yetisir E, Cass D, Well G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J 2003; 26:2618–2625. [CROSSREF]
   Web of Science ®Google Scholar
• Fletcher C, Peto R, Tinker C. The Natural History of Chronic Bronchitis and Emphysema. New York: Oxford University Press, 1976:1–272.
   Google Scholar
• Antonison N R, Connett J E, Killey J P, Bailey W C, Buist A S, Conway W A Jr, Enright P L, Kanner R E, O'Hara P, Owens G R, Scanlon P D, Tashkin D P, Wise R A. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator of the rate of decline in FEV1, the lung health study. JAMA 1994; 272(19):1497–1505.
   PubMed Web of Science ®Google Scholar
• Highland K B, Strange C, Heffner J E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. Ann Intern Med 2003; 138:969–973. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sestine P, Renzoni E, Robinson S, Poole P, Ram F S. Short-acting β2-agonists for stable chronic obstructive pulmonary disease (Cochran review). Cochrane Database Syst Rev (database online) 2003; (2), Accessed July 10, 2003.
   Google Scholar
• Calvery P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsrik A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449–456. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sin D D, McAlister F A, Man S FP, Anthonisen N R. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003; 290(17):2301–2316. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Appleton S, Poole P, Smith B, Veale A, Bara A. Long-acting β2-anonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation (Cochrane review). Cochrane Database 2003; (2), Accessed July 10, 2003. [CSA]
   PubMedGoogle Scholar
• van Noord J A, Smeets J J, Custers F LJ, Korducki L, Cornelissen P J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19:639–644. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Fluge T, Gerken F, Hamilton A, Webb K, Aguilanice B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolernace in COPD. Eur Respir J 2004; 23:832–840. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Burge P S, Calvery P MA, Jones P W, Spencer S, Anderson J A, Maslen T K. On behalf of the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297–1305. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hanania N A, Darken P, Horstam D, Reisner C, Lee B, Davis S, Shan T. The efficacy and safety of fluticasone propionate (250 µg/ salmeterol [50µg]) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124(3):834–843. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994 May; 105(5):1411–1419.
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Aerosol Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997 Dec; 112(6):1514–1521.
   PubMed Web of Science ®Google Scholar
• Friedman M, Serby C W, Menjoge S S, Wilson J D, Hilleman D E, Witek T J Jr. Pharmacoeconomics evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635–641. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lanes S F, Garrett J E, Wentworth C E, Fitzgerald J M, Karpel J P. The effect of adding ipratropium bromide to salmeterol in the treatment of acute asthma: a pooled analysis of three trials. Chest 1998 Aug; 114(2):365–372.
   PubMed Web of Science ®Google Scholar
• Karpel J P, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest 1994 Apr; 105(4):1089–1094.
   PubMed Web of Science ®Google Scholar
• Zuwallach R L, Mahler D A, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661–1670. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van Noord J A, de Munck A J, Bantje T A, Hop W CJ, Akveld M LM, Bommer A M. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878–885. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Donohue J F, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97:1014–1020. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chabra S K, Bhatnagar S. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2002; 44:91–97. [CSA]
   PubMedGoogle Scholar
• Kesten S, Rebuck A S. Is the short-term response to inhaled β-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994; 105:1042–1045. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283–1289. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Compton C H, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayers J G, Creemers J P, Schultze-Werninghaus G, Brambilla C, Barnes N C. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358:265–270. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar